AMENDMENT NO. 7 TO LICENSE AGREEMENT BETWEEN INSMED INCORPORATED AND PARI PHARMA GMBHConfidential Treatment • November 2nd, 2017 • INSMED Inc • Pharmaceutical preparations
This seventh amendment (“Amendment No. 7”) effective 21 July 2017 (“Amendment No. 7 Effective Date”) to the License Agreement dated and effective the 25th of April 2008 between PARI Pharma GmbH, a German corporation with a principal place of business at Moosstrasse 3, D-82319 Starnberg, Germany (“PARI”) and Transave, Inc., a Delaware corporation, as amended by Amendment No. 1 the 24th day of June 2009, Assignment and Amendment No. 2 the 22nd day of December 2010, Amendment No. 3 the 6th day of March 2012, Amendment No. 4 the 21st day of May 2012, Amendment No. 5 the 5th day of October 2015 and Amendment No. 6 the 9th day of October 2015 (collectively, the “Agreement”), is entered into between PARI and Insmed Incorporated (successor in interest to Transave, Inc.), with registered offices at 10 Finderne Avenue, Building 10, Bridgewater, NJ 08807-3365 (“Insmed”). PARI and Insmed shall be referred to collectively as the “Parties”.
AMENDMENT NO. 1 TO COMMERCIALIZATION AGREEMENT BETWEEN INSMED INCORPORATED AND PARI PHARMA GMBHCommercialization Agreement • November 2nd, 2017 • INSMED Inc • Pharmaceutical preparations
This first amendment (“Amendment No. 1”) effective 21 July 2017 (“Amendment No. 1 Effective Date”) to the Commercialization Agreement dated and effective the 8th of July 2014 (the “Agreement”) between PARI Pharma GmbH, a German corporation with a principal place of business at Moosstrasse 3, D-82319 Starnberg, Germany (“PARI”) and Insmed Incorporated, a Virginia corporation with a principal place of business at 10 Finderne Avenue, Building 10, Bridgewater, NJ 08807-3365 (“Insmed”), is entered into between PARI and Insmed. PARI and Insmed shall be referred to collectively as the “Parties”.
